Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes

Xia,Lei; Guo,Dianxuan; Chen,Bing

doi:10.3892/etm.2017.5238

Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes

Authors:
- Lei Xia
- Dianxuan Guo
- Bing Chen
View Affiliations

Affiliations: Department of Neurology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China, Department of Geriatrics, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, Jiangsu 223002, P.R. China
Published online on: September 29, 2017 https://doi.org/10.3892/etm.2017.5238
Pages: 5569-5575

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Parkinson's disease (PD) is characterized by a progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. Inflammation and neural degeneration are implicated in the pathogenesis of PD. Astragaloside IV (AS‑IV) has been verified to attenuate inflammation. The current study aimed to investigate the role of AS‑IV in PD and the possible molecular mechanisms. Pole, traction and swim tests were performed to examine the effects of AS‑IV on 1‑methyl‑4‑phenyl‑1, 2, 3, 6‑tetrahydropyridine (MPTP)‑generated behavioral deficiencies in vivo. Meanwhile, as for in vitro experiments, the influence of AS‑IV on cell viability was evaluated using the 3‑(4, 5‑dimethyl‑2‑thiazolyl)‑2, 5‑diphenyl‑2‑H‑tetrazolium bromide (MTT) assay, the effects of AS‑IV on 1‑methyl‑4‑phenylpyridnium ion (MPP+)‑induced cell viability changes were tested using MTT assays, cell apoptosis rates were assessed using an Annexin‑V Fluorescein isothiocyanate kit, and the expression levels of phosphorylated‑Jun N‑terminal kinase (p‑JNK), Bcl‑2‑associated X protein (Bax)/Bcl‑2 and caspase‑3 activity were assessed using western blot analysis. Behavioral tests showed that pretreatment of AS‑IV significantly alleviated MPTP‑generated behavioral deficiencies in vivo. Meanwhile, AS‑IV remarkably rescued MPP+‑induced cell viability reduction, increase in cell apoptosis rate, and upregulation of p‑JNK, Bax/Bcl‑2 ratio and caspase‑3 activity in vitro. In conclusion, AS‑IV may be a promising neuroprotective agent for PD.

View Figures

View References

1	Franco-Iborra S, Vila M and Perier C: The Parkinson disease mitochondrial hypothesis: Where are we at? Neuroscientist. 22:266–277. 2016. View Article : Google Scholar : PubMed/NCBI
2	Camilleri A and Vassallo N: The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease. CNS Neurosci Ther. 20:591–602. 2014. View Article : Google Scholar : PubMed/NCBI
3	Sanchez-Guajardo V, Tentillier N and Romero-Ramos M: The relation between α-synuclein and microglia in Parkinson's disease: Recent developments. Neuroscience. 302:47–58. 2015. View Article : Google Scholar : PubMed/NCBI
4	Xie A, Gao J, Xu L and Meng D: Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease. Biomed Res Int. 2014:6487802014. View Article : Google Scholar
5	Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, Kuno R and Suzumura A: Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem. 280:10444–10454. 2005. View Article : Google Scholar : PubMed/NCBI
6	Luo Y, Qin Z, Hong Z, Zhang X, Ding D, Fu JH, Zhang WD and Chen J: Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia. Neurosci Lett. 363:218–223. 2004. View Article : Google Scholar : PubMed/NCBI
7	Qiu YY, Zhu JX, Bian T, Gao F, Qian XF, Du Q, Yuan MY, Sun H, Shi LZ and Yu MH: Protective effects of astragaloside IV against ovalbumin-induced lung inflammation are regulated/mediated by T-bet/GATA-3. Pharmacology. 94:51–59. 2014. View Article : Google Scholar : PubMed/NCBI
8	Qiu L, Yin G, Cheng L, Fan Y, Xiao W, Yu G, Xing M, Jia R, Sun R, Ma X, et al: Astragaloside IV ameliorates acute pancreatitis in rats by inhibiting the activation of nuclear factor-κB. Int J Mol Med. 35:625–636. 2015. View Article : Google Scholar : PubMed/NCBI
9	Zhang WD, Zhang C, Liu RH, Li HL, Zhang JT, Mao C, Moran S and Chen CL: Preclinical pharmacokinetics and tissue distribution of a natural cardioprotective agent astragaloside IV in rats and dogs. Life Sci. 79:808–815. 2006. View Article : Google Scholar : PubMed/NCBI
10	Seifert G, Schilling K and Steinhauser C: Astrocyte dysfunction in neurological disorders: A molecular perspective. Nat Rev Neurosci. 7:194–206. 2006. View Article : Google Scholar : PubMed/NCBI
11	Kobayashi K, Hayashi M, Nakano H, Fukutani Y, Sasaki K, Shimazaki M and Koshino Y: Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease. Neuropathol Appl Neurobiol. 28:238–251. 2002. View Article : Google Scholar : PubMed/NCBI
12	Szydlowska K, Zawadzka M and Kaminska B: Neuroprotectant FK506 inhibits glutamate-induced apoptosis of astrocytes in vitro and in vivo. J Neurochem. 99:965–975. 2006. View Article : Google Scholar : PubMed/NCBI
13	Lee J, Ziering A, Heineman SD and Berger L: Piperidine derivatives; 2-phenyl- and 2-phenylalkyl-piperidines. J Org Chem. 12:885–893. 1947. View Article : Google Scholar : PubMed/NCBI
14	Pereira E A C and Aziz T Z: Parkinson's disease and primate research: past, present, and future. Postgraduate medical journal. 82:293–299. 2006. View Article : Google Scholar : PubMed/NCBI
15	Porras G, Li Q and Bezard E: Modeling Parkinson's disease in primates: the MPTP model. Cold Spring Harbor perspectives in medicine. 2:a0093082012. View Article : Google Scholar : PubMed/NCBI
16	Seniuk NA, Tatton WG and Greenwood CE: Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 527:7–20. 1990. View Article : Google Scholar : PubMed/NCBI
17	Hantraye P, Varastet M, Peschanski M, Riche D, Cesaro P, Willer JC and Maziere M: Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience. 53:169–178. 1993. View Article : Google Scholar : PubMed/NCBI
18	Przedborski S and Jackson-Lewis V: Mechanisms of MPTP toxicity. Mov Disord. 13 Suppl 1:S35–S38. 1998.
19	Dauer W and Przedborski S: Parkinson's disease: Mechanisms and models. Neuron. 39:889–909. 2003. View Article : Google Scholar : PubMed/NCBI
20	Ogawa N, Hirose Y, Ohara S, Ono T and Watanabe Y: A sireple quantitative hradykinesia test in MPIP treated mice. Res Commun Chem Pathol Pharmacol. 50:435–441. 1985.PubMed/NCBI
21	Kubara H, Higuchi Y and Tadokoro S: Effects of central depressants on rota-rod and action performances in mice. Jpn J Pharmacol. 27:117–126. 1977. View Article : Google Scholar : PubMed/NCBI
22	Donnan GA, Willjs GL, Kaczmarczyk SJ and Rowe P: Motor function in the l, methyl-4-phenyl-l,2,3,6-tetrahydropyridine treated mouse. J Neurol Sci. 77:185–191. 1987. View Article : Google Scholar : PubMed/NCBI
23	Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell. 103:239–252. 2000. View Article : Google Scholar : PubMed/NCBI
24	Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL and Davis RJ: A cytoplasmic inhibitor of the JNK signal transduction pathway. Science. 277:693–696. 1997. View Article : Google Scholar : PubMed/NCBI
25	Saporito MS, Thomas BA and Scott RW: MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem. 75:1200–1208. 2000. View Article : Google Scholar : PubMed/NCBI
26	Xia XG, Harding T, Weller M, Bieneman A, Uney JB and Schulz JB: Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA. 98:pp. 10433–10438. 2001, View Article : Google Scholar : PubMed/NCBI
27	Lotharius J, Falsig J, van Beek J, Payne S, Dringen R, Brundin P and Leist M: Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci. 25:6329–6342. 2005. View Article : Google Scholar : PubMed/NCBI
28	Findley HW, Gu L, Yeager AM and Zhou M: Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood. 89:2986–2993. 1997.PubMed/NCBI
29	Mandir AS, Przedborski S, JacksonLewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, Hoffman BE, Guastella DB, Dawson VL and Dawson TM: Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci USA. 96:pp. 5774–5779. 1999, View Article : Google Scholar : PubMed/NCBI
30	O'Malley KL, Liu J, Lotharius J and Holtz W: Targeted expression of BCL-2 attenuates MPP+ but not 6-OHDA induced cell death in dopaminergic neurons. Neurobiol Dis. 14:43–51. 2003. View Article : Google Scholar : PubMed/NCBI
31	Cory S and Adams JM: The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer. 2:647–656. 2002. View Article : Google Scholar : PubMed/NCBI
32	Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R and Verna JM: Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol. 65:135–172. 2001. View Article : Google Scholar : PubMed/NCBI
33	Salvesen GS: Caspases: Opening the boxes and interpreting the arrows. Cell Death Differ. 9:3–5. 2002. View Article : Google Scholar : PubMed/NCBI
34	Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ and Los M: Apoptosis and cancer: Mutations within caspase genes. J Med Genet. 46:497–510. 2009. View Article : Google Scholar : PubMed/NCBI
35	Zhang ZG, Wu L, Wang JL, Yang JD, Zhang J, Zhang J, Li LH, Xia Y, Yao LB, Qin HZ and Gao GD: Astragaloside IV prevents MPP+-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production. Mol Cell Biochem. 364:209–216. 2012. View Article : Google Scholar : PubMed/NCBI